Prelude Capital Management, LLC Esperion Therapeutics, Inc. Transaction History
Prelude Capital Management, LLC
- $1.5 Billion
- Q4 2024
A detailed history of Prelude Capital Management, LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 119,675 shares of ESPR stock, worth $217,808. This represents 0.02% of its overall portfolio holdings.
Number of Shares
119,675
Previous 34,800
243.89%
Holding current value
$217,808
Previous $57,000
361.4%
% of portfolio
0.02%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ESPR
# of Institutions
215Shares Held
129MCall Options Held
1.78MPut Options Held
1.27M-
Wasatch Advisors Inc Salt Lake City, UT24.5MShares$44.6 Million0.27% of portfolio
-
Black Rock Inc. New York, NY14MShares$25.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$21.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$18.1 Million0.44% of portfolio
-
Morgan Stanley New York, NY6.31MShares$11.5 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $121M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...